Explore UAB

Cystic Fibrosis Research Center

Could the cure for cystic fibrosis be discovered in Birmingham, Alabama?

The UAB Gregory Fleming James Cystic Fibrosis Research Center is a university-wide interdisciplinary research center funded by the National Institutes of Health, the Cystic Fibrosis Foundation, and institutional resources dedicated to fostering an innovative, multidisciplinary environment to pursue,

Events Leadership Contact

Core Facilities

Offering the most high-impact tools and techniques in CF science

Learn more

Seminars and Workshops

Supplementing the intellectual and technical expertise of members

Learn more

Patient Care

We provide state-of-the-art care for approximately 400 CF patients

Learn more

We are pleased to announce that, after a national search, Brian R. Davis, Ph.D., has been named the director of the UAB Gregory Fleming James Cystic Fibrosis Research Center (CFRC). As director, Dr. Davis will advance the mission of the CFRC to support cutting-edge research in basic science, pathophysiology, therapeutics, translational and precision medicine, clinical implementation, and genetic therapies of cystic fibrosis and related disorders in the U.S. and around the world.

Dr. Davis joins UAB from McGovern Medical School at the University of Texas Health Science Center at Houston. Since 2012, he has served as director of the Center for Stem Cell and Regenerative Medicine (CSCRM) at the Brown Foundation Institute of Molecular Medicine, where he is professor and holds the C. Harold and Lorine G. Wallace Distinguished University Chair. He also has directed the Senator Lloyd and B.A. Bentsen Center for Stroke Research.


BrianRDavisPhD

Dr. Davis leads a robust cystic fibrosis (CF) research program, funded by both the NIH and Cystic Fibrosis Foundation (CFF), comprising two main areas of investigation: Developing a gene editing-based therapeutic and potential cure, initially for patients with CF who produce little-to-no CFTR protein, and eventually to be applied more broadly. Developing and utilizing assays employing CF iPSC-derived airway epithelium to identify those patients with CF who may benefit therapeutically from currently available modulators or future small molecule drugs.

At UTHealth, Dr. Davis has also served as a dedicated mentor to faculty, postdoctoral fellows, research staff, and graduate and medical students.

We look forward to welcoming Dr. Davis. His impressive track record of collaborative leadership, innovative research, and commitment to training will strengthen and expand the already exceptional impact of the Gregory Fleming James Cystic Fibrosis Research Center.